Dr. Antonio Marchini

Since 2021, Dr Antonio Marchini has served as a Scientific Officer at the Joint Research Centre of the European Commission. In this role, he collaborates with his Team on developing novel methods and reference materials for more efficient pathogen surveillance. In 2006–2021, Dr Marchini held the position of Principal Investigator at the German Cancer Research Center (DKFZ), in Heidelberg, Germany. Additionally, in 2016–2021, he was the Head of the Laboratory of Oncolytic Virus Immuno Therapeutics (LOVIT), a joint research unit between the Luxembourg Institute of Health and DKFZ. The focus of LOVIT was to advance novel anticancer (immune) therapies based on oncolytic autonomous parvoviruses (PVs), with the aim of translating these innovations into clinical applications. Dr Marchini earned his PhD from the University of Heidelberg in 2001, working on identifying new cellular proteins interacting with human papillomavirus 16 E7 oncoprotein. Before becoming Principal Investigator, he worked as a Postdoctoral Scientist at the University of Heidelberg on the characterization of the cellular functions of the SHOX homeodomain protein. Since 2020, Dr Marchini has been an invited academic editor for Cancers. He played a pivotal role in coordinating, along with Carolina Ilkow and Alan Melcher, a Special Issue on Oncolytic Virus Immunotherapy. Additionally, he spearheaded the creation of the Topical Collection titled "Advances and Future Prospects in Oncolytic Virus Immunotherapy."